Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Ander Mayor Ibarguren"'
Autor:
Pedro Rodríguez‐Jiménez, Ander Mayor Ibarguren, Beatriz Butrón‐Bris, Luisa Martos‐Cabrera, Mar Llamas‐Velasco
Publikováno v:
JEADV Clinical Practice, Vol 2, Iss 2, Pp 379-381 (2023)
Externí odkaz:
https://doaj.org/article/1060227691164a0b9a352f7f8dd6106d
Autor:
Ander Mayor Ibarguren, MD, Espinosa Arranz Enrique, MD, Peiteado Lopez Diana, MD, Custodio Ana, MD, Herranz Pinto Pedro, PhD
Publikováno v:
JAAD Case Reports, Vol 11, Iss , Pp 84-89 (2021)
Externí odkaz:
https://doaj.org/article/a0606d2f156d4800a5d997fa1edc36cf
Autor:
Ander Mayor Ibarguren, Jéssica González Ramos, María Beato Merino, Rocío Maseda Pedrero, Cristina Gómez Fernández, Pedro Herranz Pinto
Publikováno v:
Indian Journal of Dermatology, Vol 60, Iss 4, Pp 423-423 (2015)
Cirsoid aneurysm is a small vascular proliferation characterized by small to medium-sized channels with features of arteries and veins, that present as small, blue or red asymptomatic papule. We report a case of a crisoid aneurysm on the forhead of a
Externí odkaz:
https://doaj.org/article/fc1bfeb794fa4da6bb8f693936290c42
Autor:
Alberto M Borobia, Antonio J Carcas, Ana Martínez-Feito, Alicia Marín-Candón, Irene García-García, Pedro Arias, Lucía Díaz-García, Rosa Feltes Ochoa, Natalia Hernández Cano, Pedro Herranz Pinto, María Jiménez González, Eduardo López -Granados, Ander Mayor-Ibarguren, Rocío Rosas-Alonso, Enrique Seco-Meseguer
Publikováno v:
BMJ Open, Vol 13, Iss 7 (2023)
Introduction There is a need to optimise the management of atopic dermatitis (AD), improving the efficacy of treatments and reducing the toxicity associated with them. Although the efficacy of ciclosporine (CsA) in the treatment of AD has been thorou
Externí odkaz:
https://doaj.org/article/9e05eb111cc84c8cbe81e7a28ab6c2b5
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Externí odkaz:
https://doaj.org/article/b1eb618da6ea41789c90a409ae39c55e
Autor:
Espinosa Arranz Enrique, Ander Mayor Ibarguren, Custodio Ana, Peiteado Lopez Diana, Herranz Pinto Pedro
Publikováno v:
JAAD Case Reports, Vol 11, Iss, Pp 84-89 (2021)
JAAD Case Reports
JAAD Case Reports
Immune checkpoint inhibitors (ICI) such as anti-programmed cell death protein 1 (PD-1) or anti-programmed death-ligand 1 (PDL-1) antibodies represent a breakthrough in the treatment of advanced neoplasms such as melanoma, lung, or renal cancer. The t
Publikováno v:
Dermatology and therapy. 12(3)
Xerosis is a common skin side effect of current anticancer therapies, including chemotherapy, targeted therapy, radiotherapy, and hormonotherapy. We evaluated the effectiveness of an emollient PLUS containing an Aquaphilus dolomiae extract (ADE-G1) f
Autor:
Lucía Quintana Castanedo, Eloy José Tarín Vicente, Pedro Herranz Pinto, Ander Mayor Ibarguren
Publikováno v:
Dermatologic Therapy. 34
Autor:
Ander Mayor Ibarguren, Marta Feito Rodríguez, Almudena Nuno-Gonzalez, Elena Bravo, Pedro Herranz Pinto, Kyrylo Magaletsky, María J. Beato
Publikováno v:
Journal of the European Academy of Dermatology and Venereology
Coronavirus disease 2019 (COVID-19) is a multisystemic disease with multiple symptoms. While some of them, such as respiratory problems or gastrointestinal disturbances, are common to other viral infections; others like anosmia or dysgeusia seem to b
Publikováno v:
Piel. 32:298-304